Targeted chronic myeloid leukemia therapy: Seeking a cure

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Chronic myeloid leukemia (CML) was historically treated with cytoreductive therapies or interferon alpha (IFNalpha), offering limited long-term survival.
• Allogeneic hematopoietic stem cell transplant (HSCT) provides curative potential but has limited applicability due to patient age, donor availability, and procedure morbidity.

Purpose of the Study:

• To review the impact of imatinib on CML therapy.
• To discuss the clinical trials supporting imatinib's efficacy.
• To outline the adverse effects associated with imatinib use.

Main Methods:

• Review of clinical trials, including the International Randomized Study of Interferon (IRIS) trial.
• Analysis of imatinib's mechanism of action as a BCR-ABL tyrosine kinase inhibitor.
• Evaluation of treatment outcomes, including progression-free survival and response rates.

Main Results:

• The IRIS trial demonstrated durable responses to imatinib, with a 5-year progression-free survival of 93% in CML patients.
• Imatinib is generally well-tolerated, with common toxicities including myelosuppression, edema, and gastrointestinal upset.
• Resistance to imatinib can develop, often due to BCR-ABL mutations, necessitating alternative therapies like dasatinib.

Conclusions:

• Imatinib has transformed CML treatment, allowing approximately 90% of patients in chronic phase to achieve durable responses and improved long-term survival.
• Second-generation inhibitors like dasatinib offer therapeutic options for imatinib-resistant mutations, though T315I remains a challenge.